{"id":10332,"date":"2026-04-21T13:33:15","date_gmt":"2026-04-21T13:33:15","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/10332\/"},"modified":"2026-04-21T13:33:15","modified_gmt":"2026-04-21T13:33:15","slug":"anthropic-reportedly-acquires-medical-ai-startup-coefficient-bio-qualifacts-acquires-methodone","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/10332\/","title":{"rendered":"Anthropic Reportedly Acquires Medical AI Startup Coefficient Bio | Qualifacts Acquires MethodOne"},"content":{"rendered":"

Check out today\u2019s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A<\/a>.<\/p>\n

Anthropic Reportedly Acquires Medical AI Startup Coefficient Bio for $400M+<\/p>\n

Anthropic PBC<\/a> has reportedly acquired Coefficient Bio Inc.<\/a>, a provider of artificial intelligence software for medical researchers.<\/p>\n

Half the startup\u2019s stock was owned by a healthcare-focused venture capital firm called Dimension. The fund informed investors of the acquisition in a letter that was\u00a0published<\/a>\u00a0today by journalist Eric Newcomer. According to the document, Anthropic is paying more than $400 million in stock for the company.<\/p>\n

Coefficient was founded about eight months ago by a group of former pharmaceutical executives and researchers. According to Newcomer, the company developed AI models optimized for biology research. In a\u00a0January post<\/a>\u00a0on X, one of the company\u2019s co-founders stated that the company\u2019s technology would \u201cchange everything about how the industry learns and makes decisions.\u201d That hints that Coefficient\u2019s models are built to automate particularly high-impact research tasks.<\/p>\n

One of the most important medical research workflows to which startups are applying AI is small molecule discovery. Small molecules are biological building blocks about one nanometer in size that form the basis of most pharmaceuticals. Manas AI Inc., a startup active in that area,\u00a0estimates<\/a>\u00a0AI can speed up certain aspects of the discovery workflow by a factor of 100.<\/p>\n

One way researchers determine whether a small molecule has therapeutic applications is by checking its ability to dock to pathogens. If a small molecule can\u2019t dock to a pathogen, it can\u2019t neutralize it\u2026<\/p>\n

Full release here<\/a>, originally announced April 3rd, 2026.<\/p>\n

Qualifacts Acquires MethodOne to Fully Integrate Medication-Assisted Treatment into its EHR Platforms for Substance Use Disorder Providers<\/p>\n

Acquisition Strengthens Qualifacts\u2018 Position as the Leading Behavioral Health EHR Provider, Enabling SUD and OTP Providers to Better Manage Controlled Medication Dispensing and Clinical Workflows in a Unified Solution<\/p>\n

Qualifacts<\/a>, the leading behavioral health technology partner specializing in AI-powered electronic health record (EHR) and data solutions, today announced the acquisition of\u00a0MethodOne by Computalogic<\/a>, a comprehensive controlled-medication dispensing software purpose-built for opioid treatment programs (OTPs) and substance use disorder (SUD) providers. The acquisition brings together Qualifacts\u2019 award-winning EHR platforms with MethodOne\u2019s best-in-class medication dispensing and inventory management capabilities, creating a single, fully integrated solution for the behavioral healthcare market.\u00a0<\/p>\n

The\u00a0MethodOne\u00a0integration expands\u00a0Qualifacts\u2019 EHR capabilities, closing a critical gap for SUD and complex mental health providers that increasingly require integrated medication-assisted treatment (MAT) and medications for opioid use disorder (MOUD) dispensing.\u00a0There are approximately 2,224 OTPs\u00a0operating\u00a0in the United States, a segment that has grown at 5.6% CAGR since 2019 and collectively treats over half a billion patients annually, the majority of whom are Medicaid beneficiaries.\u00a0Qualifacts\u2019 existing customer feedback\u00a0indicates\u00a0that agencies are actively shifting from office-based opioid treatment (OBOT) models to OTPs to take advantage of simpler billing workflows, accelerating demand for an integrated platform that can support both clinical and dispensing needs.\u00a0<\/p>\n

\u201cThis acquisition is a direct response to what our customers are telling us they need,\u201d said Josh Schoeller, CEO at Qualifacts. \u201cLarge SUD and mental health organizations require an integrated MAT and MOUD solution to operate effectively, and until now, that has meant cobbling together multiple systems. Bringing MethodOne into the Qualifacts family means our customers get a more complete behavioral healthcare EHR platform, with a single support relationship and a unified roadmap.\u201d\u00a0<\/p>\n

OTP providers operate under some of the most demanding regulatory requirements in healthcare, subject to overlapping oversight from the DEA, SAMHSA, and state agencies. With MethodOne fully integrated into Qualifacts EHRs, organizations can significantly reduce compliance and billing burden by unifying clinical documentation and controlled substance dispensing workflows, while eliminating duplicative data entry and the risks that come with managing disconnected systems. Providers can spend less time managing software and more time delivering care.\u00a0<\/p>\n

MethodOne has built a strong reputation among SUD treatment providers for feature-rich functionality and ease of use. Its functionality is regarded as superior to existing alternatives in the market\u2026<\/p>\n

Full release here<\/a>, originally announced April 7th, 2026.<\/p>\n

Get Fresh Healthcare & IT Stories Delivered Daily<\/p>\n

Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter.<\/p>\n

We respect your privacy and will never sell or give out your contact information<\/p>\n","protected":false},"excerpt":{"rendered":"Check out today\u2019s featured companies who have recently completed an M&A deal, and be sure to check out…\n","protected":false},"author":2,"featured_media":10333,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[53,1479,8711,8712,8713,8714,8715,8716,8717,8718,8719,8720,8721],"class_list":{"0":"post-10332","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-anthropic","8":"tag-anthropic","9":"tag-anthropic-pbc","10":"tag-coefficient-bio","11":"tag-coefficient-bio-inc","12":"tag-computalogic","13":"tag-eric-newcomer","14":"tag-health-it-acquisitions","15":"tag-healthcare-ma","16":"tag-josh-schoeller","17":"tag-manas-ai-inc","18":"tag-methodone","19":"tag-methodone-by-computalogic","20":"tag-qualifacts"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/10332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=10332"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/10332\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/10333"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=10332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=10332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=10332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}